Classifying non-small cell lung tumors by growth patterns had a strong predictive value for measures of survival.

Growth pattern refers to the tumor growth in relation to normal lung tissue and blood vessels within the tumor; tumors need these blood vessels to survive and scientists have been studying these patterns in an effort to individualize therapy.

In data presented at the AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer, researchers classified tumors into three growth patterns: destructive, alveolar and papillary. In destructive patterns, the tumor makes its own microenvironment for further growth. In the alveolar pattern, the tumor uses the microenvironment of the lung to grow, and in the papillary pattern the normal lung tissue is preserved in the presence of a new microenvironment.

Peyman Sardari Nia, M.D., Ph.D., a postdoctoral fellow at the University of Antwerp in Belgium, and colleagues tested this classification to see if they had prognostic value in patients with non-small cell lung cancer.

"The current management, treatment and prognosis of lung cancer is treatment based on tumor-node-metastasis staging," said Sardari Nia. "Unfortunately, tumor node metastasis does not account for survival differences in the same stage and does not provide information about the biology of the tumor."

For this study, Sardari Nia and colleagues enrolled 432 patients who had a complete resection for primary non-small cell lung cancer. The researchers followed the patients for about 50 months. According to the classifications outlined, 71.1 percent had a destructive growth pattern, 13.9 percent had a papillary growth pattern and 15 percent had an alveolar growth pattern. These growth patterns were independent predictors for overall survival, disease-specific survival and disease-free survival.

Patients with an alveolar growth pattern had a 52 percent greater chance of a poor prognosis for overall survival and a nearly two-fold increased risk for poorer disease-specific survival and for disease-free survival.

"This biological classification provides explanations for survival differences at the same disease stage," said Sardari Nia. "Additionally, these growth patterns represent distinct biologic subtypes implying that different growth patterns might respond differently to the pallet of treatment modalities, paving the way for individualization of the patient's treatment."

Source
American Association for Cancer Research (AACR)

Tag Cloud

Order Advair (Fluticasone) Without Prescription
Order Antabuse (Disulfiram) Without Prescription
Order Armour (Thyroid) Without Prescription
Order Atripla (Efavirenz) Without Prescription
Order Augmentin (Clavulanate) Without Prescription
Order Benicar (Olmesartan) Without Prescription
Order Chantix (Varenicline) Without Prescription
Order Clonidine (Catapres) Without Prescription
Order Elavil (Amitriptyline) Without Prescription
Order Erythromycin (Robimycin) Without Prescription
Order Famvir (Famciclovir) Without Prescription
Order Hydrochlorothiazide (Microzide) Without Prescription
Order Imitrex (Sumatriptan) Without Prescription
Order Inderal (Propranolol) Without Prescription
Order Lasix (Furosemide) Without Prescription
Order Lumigan (Bimatoprost) Without Prescription
Order Medrol (Methylprednisolone) Without Prescription
Order Misoprostol (Cytotec) Without Prescription
Order Naltrexone (Revia) Without Prescription
Order Nexium (Esomeprazole) Without Prescription
Order Nolvadex (Tamoxifen) Without Prescription
Order Norvasc (Amlodipine Besylate) Without Prescription
Order Ortho Tri-Cyclen (TriNessa) Without Prescription
Order Retin-A (Tretinoin) Without Prescription
Order Spiriva (Tiotropium) Without Prescription
Order Suprax (Cefixime) Without Prescription
Order Synthroid (Levothyroxine) Without Prescription
Order Ventolin (Albuterol) Without Prescription
Order Zithromax (Azithromycin) Without Prescription